
    
      This is an observational, prospective, single-arm, post-market registry designed to collect
      real-world clinical and device specific outcomes of the GORE® TAG® Conformable Thoracic Stent
      Graft featuring ACTIVE CONTROL System (CTAG Device with ACTIVE CONTROL) in the treatment of
      aortic disease as part of routine clinical practice. A maximum of 20 clinical investigative
      sites in Europe will participate and up to 125 patients will be enrolled in this registry.
      All consecutive patients meeting protocol selection criteria, consented, with an intention to
      be treated with the CTAG Device with ACTIVE CONTROL will be included and followed through one
      year per institutional standard of care.
    
  